Skip to main content
Premium Trial:

Request an Annual Quote

DASA Offering Natera's Panorama NIPD in Brazil

NEW YORK (GenomeWeb News) – DASA Group and Natera have reached a deal to offer Natera's non-invasive prenatal diagnostic test in Brazil, the companies announced on Thursday.

Financial and other terms were not disclosed.

Called Panorama, Natera's test detects trisomy 21, 18, and 13 and monosomy X with a simple blood draw from the mother. Panorama was launched in December.

In June, San Carlos, Calif.-based Natera announced a deal with Unilabs to offer the test in Switzerland and Scandinavia. Natera also has distribution deals with Arup Laboratories, Quest Diagnostics, and Bio-Reference Laboratories.

DASA, based in Sao Paulo, offers diagnostic services in Brazil. Panorama will be offered through the Delboni brands Sergio Franco and Alta, which are part of DASA.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.